High-sensitivity C-reactive protein and interleukin-6-dominant inflammation and ischemic stroke risk: The Northern Manhattan study

Stroke

Volumn 45, Issue 4, 2014, Pages 979-987

  Luna, Jorge M ^a   Moon, Yeseon P ^b   Liu, Khin M ^b   Spitalnik, Steven ^b   Paik, Myunghee C ^a   Cheung, Keun ^a   Sacco, Ralph L ^c   Elkind, Mitchell S V ^a,b,d  

^a Department of Epidemiology Mailman School of Public Health ^*  (United States)

^b Departments of Neurology Columbia University College of Physicians and Surgeons ^*  (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

Author keywords

Biomarkers; Inflammation; Ischemic stroke; Prevention and control

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 6;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CONSTRUCT VALIDITY; ETHNICITY; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREVENTION AND CONTROL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY ANALYSIS; VERY ELDERLY;

BIOMARKERS; INFLAMMATION; ISCHEMIC STROKE; PREVENTION AND CONTROL;

ADULT; AGED; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; C-REACTIVE PROTEIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; NEW YORK CITY; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; STROKE;

EID: 84897410285     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.002289     Document Type: Article

References (42)

1. Corrado E, Rizzo M, Coppola G, Fattouch K, Novo G, Marturana I, et al. An update on the role of markers of inflammation in atherosclerosis. J Atheroscler Thromb. 2010;17:1-11.
2. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: An individual participant meta-Analysis. Lancet. 2010;375:132-40.
3. Elkind MS, Luna JM, Moon YP, Liu KM, Spitalnik SL, Paik MC, et al. High-sensitivity C-reactive protein predicts mortality but not stroke: The Northern Manhattan Study. Neurology. 2009;73:1300-1307.
4. Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P, Gorman DN, et al. Interleukin-6 receptor pathways in coronary heart disease: A collaborative meta-Analysis of 82 studies. Lancet. 2012;379:1205-13.
5. März W, Winkler K, Nauck M, Böhm BO, Winkelmann BR. Effects of statins on C-reactive protein and interleukin-6 (the Ludwigshafen Risk and Cardiovascular Health study). Am J Cardiol. 2003;92:305-308.
6. Pardina E, Ferrer R, Baena-Fustegueras JA, Rivero J, Lecube A, Fort JM, et al. Only C-reactive protein, but not TNF-α or IL6, reflects the improvement in inflammation after bariatric surgery. Obes Surg. 2012;22:131-139.
7. Elkind MS, Luna JM, Moon YP, Liu KM, Spitalnik SL, Paik MC, et al. High-sensitivity C-reactive protein predicts mortality but not stroke: The Northern Manhattan Study. Neurology. 2009;73:1300-1307.
8. Collaborators NMSS, Sacco RL, Boden-Albala B, Gan R, Chen X, Kargman DE, et al. Stroke Incidence among White, Black, and Hispanic Residents of an Urban Community: The Northern Manhattan Stroke Study. Am J Epidemiol. 1998;147:259-268.
9. Greene HL, Richardson DW, Barker AH, Roden DM, Capone RJ, Echt DS, et al. Classification of deaths after myocardial infarction as arrhythmic or nonarrhythmic (the Cardiac Arrhythmia Pilot Study). Am J Cardiol. 1989;63:1-6.
10. Wang CY, Chen HY. Augmented inverse probability weighted estimator for Cox missing covariate regression. Biometrics. 2001;57:414-419.
11. Xu Q, Paik MC, Rundek T, Elkind MS, Sacco RL. Reweighting estimators for Cox regression with missing covariate data: Analysis of insulin resistance and risk of stroke in the Northern Manhattan Study. Stat Med. 2011;30:3328-3340.
12. Galea S, Riddle M, Kaplan GA. Causal thinking and complex system approaches in epidemiology. Int J Epidemiol. 2010;39:97-106.
13. Cao JJ, Arnold AM, Manolio TA, Polak JF, Psaty BM, Hirsch CH, et al. Association of carotid artery intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: The Cardiovascular Health Study. Circulation. 2007;116:32-38.
14. Zakai NA, Katz R, Jenny NS, Psaty BM, Reiner AP, Schwartz SM, et al. Inflammation and hemostasis biomarkers and cardiovascular risk in the elderly: The Cardiovascular Health Study. J Thromb Haemost. 2007;5:1128-1135.
15. Jenny NS, French B, Arnold AM, Strotmeyer ES, Cushman M, Chaves PHM, et al. Long-Term assessment of inflammation and healthy aging in late life: The Cardiovascular Health Study All Stars. J Gerontol A Biol Sci Med Sci. 2012;67:970-976.
16. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Chambless LE, et al. Lipoprotein-Associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-Aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med. 2005;165:2479-2484.
17. Folsom AR, Chambless LE, Ballantyne CM, Coresh J, Heiss G, Wu KK, et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: The atherosclerosis risk in communities study. Arch Intern Med. 2006;166:1368-1373.
18. Blaha MJ, Budoff MJ, DeFilippis AP, Blankstein R, Rivera JJ, Agatston A, et al. Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: Implications for the JUPITER population from MESA, a population-based cohort study. Lancet. 2011;378:684-692.
19. van den Ham HJ, de Jager W, Bijlsma JW, Prakken BJ, de Boer RJ. Differential cytokine profiles in juvenile idiopathic arthritis subtypes revealed by cluster analysis. Rheumatology (Oxford). 2009;48:899-905.
20. Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: Induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood. 1994;83:113-118.
21. Zhu RZ, Xiang D, Xie C, Li JJ, Hu JJ, He HL, et al. Protective effect of recombinant human IL-1Ra on CCl4-induced acute liver injury in mice. World J Gastroenterol. 2010;16:2771-2779.
22. Westlund KN, Zhang L, Ma F, Oz HS. Chronic inflammation and pain in a tumor necrosis factor receptor (TNFR) (p55/p75-/-) dual deficient murine model. Transl Res. 2012;160:84-94.
23. Kimizuka K, Nakao A, Nalesnik MA, Demetris AJ, Uchiyama T, Ruppert K, et al. Exogenous IL-6 inhibits acute inflammatory responses and prevents ischemia/reperfusion injury after intestinal transplantation. Am J Transplant. 2004;4:482-494.
24. Kasapis C, Thompson PD. The effects of physical activity on serum C-reactive protein and inflammatory markers: A systematic review. J Am Coll Cardiol. 2005;45:1563-1569.
25. Petersen AM, Pedersen BK. The role of IL-6 in mediating the anti-inflammatory effects of exercise. J Physiol Pharmacol. 2006;57(suppl 10):43-51.
26. Murray PJ. The primary mechanism of the IL-10-regulated antiinflammatory response is to selectively inhibit transcription. Proc Natl Acad Sci U S A. 2005;102:8686-8691.
27. Starkie R, Ostrowski SR, Jauffred S, Febbraio M, Pedersen BK. Exercise and IL-6 infusion inhibit endotoxin-induced TNF-Alpha production in humans. FASEB J. 2003;17:884-886.
28. Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N, et al. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity. 2001;14:705-714.
29. Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF, et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest. 1998;101:311-320.
30. Alley DE, Crimmins E, Bandeen-Roche K, Guralnik J, Ferrucci L. Three-year change in inflammatory markers in elderly people and mortality: The Invecchiare in Chianti study. J Am Geriatr Soc. 2007;55:1801-1807.
31. Shine B, de Beer FC, Pepys MB. Solid phase radioimmunoassays for human C-reactive protein. Clin Chim Acta. 1981;117:13-23.
32. Weinhold B, Rüther U. Interleukin-6-dependent and-independent regulation of the human C-reactive protein gene. Biochem J. 1997;327(pt 2):425-429.
33. Kronmal RA. Spurious correlation and the fallacy of the ratio standard revisited. J R Stat Soc Series A Stat Soc. 1993;156:379-392.
34. Fiscella K, Franks P, Gold MR, Clancy CM. Inequality in quality: Addressing socioeconomic, racial, and ethnic disparities in health care. JAMA. 2000;283:2579-2584.
35. Hu Y, Tong G, Xu W, Pan J, Ryan K, Yang R, et al. Anti-inflammatory effects of simvastatin on adipokines in type 2 diabetic patients with carotid atherosclerosis. Diab Vasc Dis Res. 2009;6:262-268.
36. Devaraj S, Chan E, Jialal I. Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab. 2006;91:4489-4496.
37. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 2001;103:1933-1935.
38. Lapice E, Maione S, Patti L, Cipriano P, Rivellese AA, Riccardi G, et al. Abdominal adiposity is associated with elevated C-reactive protein independent of BMI in healthy nonobese people. Diabetes Care. 2009;32:1734-1736.
39. Galcheva SV, Iotova VM, Yotov YT, Bernasconi S, Street ME. Circulating proinflammatory peptides related to abdominal adiposity and cardiometabolic risk factors in healthy prepubertal children. Eur J Endocrinol. 2011;164:553-558.
40. Barnard EE. JUPITER: Observation of the great red spot. Science. 1881;2:9-10.
41. Fowler-Brown A, Corbie-Smith G, Garrett J, Lurie N. Risk of cardiovascular events and death-does insurance matter? J Gen Intern Med. 2007;22:502-507.
42. Ranjit N, Diez-Roux AV, Shea S, Cushman M, Ni H, Seeman T. Socioeconomic position, race/ethnicity, and inflammation in the multiethnic study of atherosclerosis. Circulation. 2007;116:2383-2390.